PT Kalbe Farma Tbk : Herbal Medicine Clinical Trial as Immunomodulators on COVID-19 Patients

Herbal Medicine Clinical Trial as Immunomodulators on COVID-19 Patients

Jakarta, June 11, 2020 - PT Kalbe Farma Tbk (Kalbe) took part in clinical trials on herbal medicines made from Indonesian biodiversity as herbal immunomodulatory products in the handling of COVID-19 patients that is coordinated by the Covid-19 Research Consortium/BRIN. The 2 products that will take part in the clinical trial are products based on Cordyceps militaris and a combination of extracted ingredients made from extracts of red ginger, gripeweed, Green chiretta, and Ngai camphor. The clinical trial is a collaboration of the Indonesian Institute of Sciences (LIPI), Kalbe, Gadjah Mada University (UGM), and the Association of Indonesian Traditional Medicine and Herbal Medicine Developers (PDPOTJI). LIPI as the coordinator of the Indonesian Herbal medicine clinical trials also collaborates with the National Disaster Management Agency (BNPB) and the Food and Drug Monitoring Agency (BPOM) to carry out clinical trials at the Wisma Atlet Emergency Hospital, supported by the Indonesian Lung Doctors Association (PDPI), Military Health Center, and Research and Development of the Ministry of Health. The clinical trial will begin on June 8, 2020, and is expected to be completed in August 2020

'Kalbe is committed to supporting the government through Kalbe herbal products in resolving and overcoming COVID-19, one of which is through innovation and research into herbal medicine as an immunomodulator in COVID-19 patients' handling,' said Sie Djohan, Director of PT Kalbe Farma Tbk. 'We have conducted a literature review of superior herbal products that have effectiveness, safety, and have local content value as well as the availability of raw materials. We hope that the benefits of the herbal product can be felt by the community in helping to strengthen the body's immunity and to be able to remain productive in the new normal periods,' continued Djohan.

Previously, Kalbe already has a product that is based on the Cordyceps militaris mushroom. The process of tissue culture, extraction, and manufacturing of Cordyceps militaris-based mushrooms are carried out in Indonesia. Cordyceps fungus has been believed to maintain the immune system and treat respiratory disorders. As a traditional medicinal plant, cordyceps contains many nutrients, such as protein, essential amino acids, peptides, vitamins (B1, B2, B12, E, K), fatty acids, and minerals as well as active ingredients cordycepin and adenosine. While other products used in clinical trials are products derived from a combination of herbs, which are made from red ginger extract, gripeweed, Green chiretta, and Ngai camphor. Indonesian natural herbal ingredients that have been trusted to maintain the body's immune system. Products with this herbal combination will soon be launched to consumers in July 2020.

Kalbe at a glance
PT Kalbe Farma Tbk ('Kalbe') was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc. ); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc. ); energy and ready-to-consume supplement drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc. ); and distribution division. Kalbe currently has approximately 40 subsidiaries and 12 production facilities with international standard and employs approximately 17,000 employees dispersed across more than 74 branches throughout Indonesia. From 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).

---oOo---

Print

0Rate this article:

No rating

Please login or register to post comments.